Publications by authors named "D Bachelet"
Objectives: Neurologic outcomes of patients under venoarterial extracorporeal membrane oxygenation (VA-ECMO) may be worsened by secondary insults of systemic origin. We aimed to assess whether sepsis, commonly observed during ECMO support, is associated with brain injury and outcomes.
Design: Single-center cohort study of the "exposed-non-exposed" type on consecutive adult patients treated by VA-ECMO.
Objectives: Lupus activity has long been considered to decline after initiation of maintenance dialysis (MD). This assumption is based on limited historical data. We aimed to describe the natural history of lupus in patients undergoing MD.
View Article and Find Full Text PDFArticle Synopsis
- Researchers studied 1,227 COVID-19 survivors to see if taking corticosteroids affected their health after leaving the hospital.
- They found that people who took corticosteroids had more health issues later compared to those who didn't, especially those on lower doses.
- The study suggests that using corticosteroids while in the hospital might lead to more problems later on for some patients.
Background: Ventilator acquired pneumonia (VAP) is a frequent and serious complication in ICU. Second episodes of VAP are common in trauma patients and may be related to severity of underlying conditions, treatment or bacterial factors of the first VAP. The aim of this study was to identify risk factors of second VAP episodes in trauma injured patients (defined as the development of a new pulmonary infection during or remotely following the first episode).
View Article and Find Full Text PDFIntroduction: Ventilator-associated pneumonia (VAP) remains the leading cause of infections treated in the intensive care units (ICU). In a personalised care approach, we hypothesise that the duration of treatment of VAP can be reduced in function of the response to treatment.
Methods And Analysis: The Antimicrobial Stewardship for Ventilator-Associated Pneumonia in Intensive Care (ASPIC) trial is a pragmatic national multicentre, phase III, non-inferiority, comparative randomised (1:1) single-blinded clinical trial.